| 货号 | 规格 | 价格 | 上海 | 北京 | 武汉 | 南京 | 购买数量 |
|---|---|---|---|---|---|---|---|
S87018-10mg |
≥98%(HPLC) | ￥359.00 | 10 | - | - | - |
|
S87018-25mg |
≥98%(HPLC) | ￥770.00 | 8 | - | - | - |
|
S87018-50mg |
≥98%(HPLC) | ￥1220.00 | 4 | - | - | - |
|
S87018-100mg |
≥98%(HPLC) | ￥1900.00 | 3 | - | - | - |
|
S87018-250mg |
≥98%(HPLC) | ￥3500.00 | 2 | - | - | - |
|
| 产品描述： | R-268712 is an orally active and selective ALK-5 inhibitor, with an IC50 of 2.5 nM. R-268712 inhibits the phosphorylation of Smad3 in a dose-dependent manner with an IC50 of 10.4 nM. R-268712 suppresses glomerulonephritis as well as glomerulosclerosis by inhibiting TGF-β signaling, which can be used in studies of renal fibrosis and cancer | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | TGFBR1:2.5 nM (IC50);Smad3:10.4 nM (IC50);ALK;TGF-beta/Smad | ||||||||||||||||||||
| 体外研究： | R-268712 (3, 10, 30, 100, 300 nM; 1 h) inhibits the phosphorylation of Smad3 in a dose-dependent manner with an IC50 of 10.4 nM in HFL-1 cells. R-268712 (3, 10, 30, 100, 300 nM; 72 h) inhibits myofibroblast transdifferentiation (MTD) from fibroblasts in a dose-dependent manner without inhibition of cell growth in HFL-1cells. Cell Viability Assay Cell Line: HFL-1 cells Concentration: 3, 10, 30, 100, 300 nM Incubation Time: 1 or 72 h Result: Inhibited the phosphorylation of Smad3 in a dose-dependent manner with an IC50 of 10.4 nM when incubation 1 h.Suppressed myofibroblast transdifferentiation (MTD) from fibroblasts in a dose-dependent manner without inhibition of cell growth when incubation after 72 h. | ||||||||||||||||||||
| 体内研究： | R-268712 (0.3, 1, 3, 10 mg/kg; p.o.; single) shows AUC0-24 values of 0.075, 0.28, 1.6 and 8.2 μg•h/mL for dosages of 0.3, 1, 3, 10 mg/kg, respectively. R-268712 (1, 3, 10 mg/kg; p.o.; single daily for 3 days) inhibits renal luciferase activity in a dose-dependent manner in UUO model. R-268712 (0.3, 1 mg/kg; p.o.; single daily for 33 days) shows renoprotective effects (improves and maintains renal function as well as inhibits glomerular sclerosis) on Thy1 nephritis model when at dosage of 1 mg/kg. Animal Model: Male WKY/Hos rats. Dosage: 0.3, 1, 3, and 10 mg/kg Administration: Oral administration; single. Result: Pharmacokinetic Parameters of R-268712 in male WKY/Hos rats (n=4) Animal Model: Male Col1a1-Luc Tg rats (10 to14-week-old; UUO model; n=5-6). Dosage: 1, 3, 10 mg/kg Administration: Oral administration; single daily for 3 days. Result: Suppressed activity of renal luciferase in a dose-dependent manner. Animal Model: Male WKY/Hos rats (4-week-old; Thy1 nephritis model; n=7). Dosage: 0.3, 1 mg/kgAdministration: Oral administration; single daily for 33 days. Result: Significantly reduced proteinuria at day 21( the repression continued until day 28), and serum creatinine level (dosage at 1 mg/kg).Apparently suppressed glomerular sclerosis by 28% and reduced the increase of the hydroxyproline content when at 1 mg/kg.Suppressed the activation of mesangial parenchymal cell and the injury of podocyte on the basis of TGF-β signaling inhibition at 1 mg/kg. | ||||||||||||||||||||
| 参考文献： | 1. Terashima H, et al. Attenuation of pulmonary fibrosis in type I collagen-targeted reporter mice with ALK-5 inhibitors. Pulm Pharmacol Ther. 2019 Feb;54:31-38. 2. Terashima H, et al. R-268712, an orally active transforming growth factor-β type I receptor inhibitor, prevents glomerular sclerosis in a Thy1 nephritis model. Eur J Pharmacol. 2014 Jul 5;734:60-6. 3. Wang H, et al. Development of small molecule inhibitors targeting TGF-β ligand and receptor: Structures, mechanism, preclinical studies and clinical usage. Eur J Med Chem. 2020 Apr 1;191:112154. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京